CASI Pharmaceuticals
Market Cap
US$281.4m
Last Updated
2021/03/06 23:21 UTC
Data Sources
Company Financials +
Executive Summary
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CASI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CASI's weekly volatility (10%) has been stable over the past year.
Market Performance
7 Day Return
-7.7%
CASI
-4.4%
US Biotechs
-0.4%
US Market
1 Year Return
26.1%
CASI
23.7%
US Biotechs
36.3%
US Market
Return vs Industry: CASI exceeded the US Biotechs industry which returned 23.7% over the past year.
Return vs Market: CASI underperformed the US Market which returned 36.3% over the past year.
Shareholder returns
| CASI | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.7% | -4.4% | -0.4% |
| 30 Day | -35.9% | -8.5% | -1.3% |
| 90 Day | -6.6% | -1.0% | 4.9% |
| 1 Year | 26.1%26.1% | 25.7%23.7% | 39.2%36.3% |
| 3 Year | -31.4%-31.4% | 12.2%6.5% | 48.7%39.2% |
| 5 Year | 163.9%163.9% | 51.4%40.0% | 117.0%92.8% |
Long-Term Price Volatility Vs. Market
How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth1 month ago | Simply Wall St
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?2 months ago | Simply Wall St
Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?Valuation
Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
3.07x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CASI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CASI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CASI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CASI is good value based on its PB Ratio (3.1x) compared to the US Biotechs industry average (3.9x).
Next Steps
Future Growth
How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
36.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CASI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CASI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CASI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CASI's revenue (46.5% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: CASI's revenue (46.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has CASI Pharmaceuticals performed over the past 5 years?
-43.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CASI is currently unprofitable.
Growing Profit Margin: CASI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of 43% per year.
Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: CASI has a negative Return on Equity (-40.58%), as it is currently unprofitable.
Next Steps
Financial Health
How is CASI Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CASI's short term assets ($83.3M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: CASI's short term assets ($83.3M) exceed its long term liabilities ($15.9M).
Debt to Equity History and Analysis
Debt Level: CASI is debt free.
Reducing Debt: CASI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CASI has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 39.1% each year.
Next Steps
Dividend
What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CASI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CASI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CASI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Wei-Wu He (55 yo)
1.92yrs
Tenure
US$9,410,827
Compensation
Dr. Wei-Wu He, Ph.D. serves as Chairman and Chief Executive Officer at CASI Pharmaceuticals, Inc since April 2, 2019 and served as its Executive Chairman from February 23, 2018 until April 2, 2019. Dr. He ...
CEO Compensation Analysis
Compensation vs Market: Wei-Wu's total compensation ($USD9.41M) is above average for companies of similar size in the US market ($USD946.79K).
Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 1.92yrs | US$9.41m | 3.78% $ 10.6m | |
| President | 1.5yrs | US$956.10k | 0.016% $ 45.7k | |
| Chief Medical Officer | 3.92yrs | US$961.35k | 0% $ 0 | |
| CFO & Principal Accounting Officer | 0.25yr | no data | 0.0081% $ 22.7k | |
| COO, General Counsel & Secretary | 12.25yrs | US$467.10k | no data | |
| Senior Vice President of Business Development | 1.92yrs | no data | no data |
1.9yrs
Average Tenure
55yo
Average Age
Experienced Management: CASI's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 1.92yrs | US$9.41m | 3.78% $ 10.6m | |
| Independent Director | 4.75yrs | US$139.00k | 0% $ 0 | |
| Independent Director | 7.92yrs | US$144.85k | 0.00015% $ 422.0 | |
| Independent Director | 6.5yrs | US$125.60k | 0% $ 0 | |
| Member of Scientific Advisory Board | 14.67yrs | no data | no data | |
| Independent Director | 7.92yrs | US$140.45k | 0% $ 0 | |
| Member of Clinical Advisory Board | 5.67yrs | no data | no data | |
| Independent Director | 6.75yrs | US$140.45k | 0% $ 0 | |
| Member of Clinical Advisory Board | 5.67yrs | no data | no data |
6.8yrs
Average Tenure
62yo
Average Age
Experienced Board: CASI's board of directors are considered experienced (6.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CASI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.
Top Shareholders
Company Information
CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: CASI Pharmaceuticals, Inc.
- Ticker: CASI
- Exchange: NasdaqCM
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$281.352m
- Shares outstanding: 123.94m
- Website: https://www.casipharmaceuticals.com
Number of Employees
Location
- CASI Pharmaceuticals, Inc.
- 9620 Medical Center Drive
- Suite 300
- Rockville
- Maryland
- 20850
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CASI | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jun 1996 |
| ENMN | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1996 |
Biography
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/06 23:21 |
| End of Day Share Price | 2021/03/05 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.